CG Oncology, Inc. (CGON)
| Market Cap | 6.27B +104.3% |
| Revenue (ttm) | 6.17M +183.6% |
| Net Income | -237.46M |
| EPS | -2.78 |
| Shares Out | 89.32M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,277,579 |
| Open | 72.01 |
| Previous Close | 72.61 |
| Day's Range | 67.43 - 73.00 |
| 52-Week Range | 37.01 - 80.97 |
| Beta | 0.35 |
| Analysts | Strong Buy |
| Price Target | 91.46 (+30.38%) |
| Earnings Date | Nov 6, 2026 |
About CGON
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with... [Read more]
Financial Performance
In 2025, CG Oncology's revenue was $4.04 million, an increase of 254.70% compared to the previous year's $1.14 million. Losses were -$161.00 million, 82.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for CGON stock is "Strong Buy." The 12-month stock price target is $91.46, which is an increase of 30.38% from the latest price.
News
CG Oncology price target lowered to $89 from $90 at Guggenheim
Guggenheim analyst Brad Canino lowered the firm’s price target on CG Oncology (CGON) to $89 from $90 and keeps a Buy rating on the shares.
CG Oncology reports Q3 EPS (64c), consensus (81c)
Reports Q3 revenue $1.61M, consensus $534,480. “We are entering an eventful period for CG Oncology (CGON) as we look forward to sharing PIVOT-006 topline data this month. As a reminder,…
CG Oncology Earnings release: Q3 2026
CG Oncology released its Q3 2026 earnings on November 6, 2026, summarizing the period's financial results.
CG Oncology Quarterly report: Q3 2026
CG Oncology has published its Q3 2026 quarterly earnings report on November 6, 2026.
CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates
DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the third quarter ended September 30, 2026, and provided business updates.
CG Oncology Slides: Investor presentation
CG Oncology has posted slides in relation to its latest quarterly earnings report, which was published on October 23, 2026.
CG Oncology Slides: Conference presentation
CG Oncology has posted slides in relation to its latest quarterly earnings report, which was published on October 14, 2026.
CG Oncology appoints Isabel Kalofonos as chief commercial officer
CG Oncology (CGON) announced the appointment of Isabel Kalofonos as chief commercial officer. Kalofonos will lead the company’s commercial strategy and execution as CG Oncology advances toward the pot...
CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer
DALLAS, Oct. 13, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. A highly accomplished biopharmaceutical exec...
CG Oncology Slides: Investor presentation
CG Oncology has posted slides in relation to its latest quarterly earnings report, which was published on September 25, 2026.
CG Oncology Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Key highlights include robust BLA progress for cretostimogene grenadenorepvec, strong differentiation through durable efficacy and operational simplicity, and a well-capitalized position supporting multiple clinical and commercial milestones. Near-term catalysts include pivotal trial data and label expansion opportunities.
CG Oncology Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Cretostimogene is advancing through multiple late-stage trials for non-muscle invasive bladder cancer, with a new phase III in BCG-exposed patients and imminent PIVOT-006 results. Manufacturing and regulatory preparations are nearly complete, and market adoption strategies focus on workflow compatibility and leveraging real-world data.
CG Oncology to Present at Upcoming Investor Conferences in September
DALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentat...
CG Oncology price target raised to $85 from $82 at Truist
Truist raised the firm’s price target on CG Oncology (CGON) to $85 from $82 and keeps a Buy rating on the shares.
CG Oncology price target lowered to $79 from $81 at RBC Capital
RBC Capital lowered the firm’s price target on CG Oncology (CGON) to $79 from $81 and keeps an Outperform rating on the shares.
CG Oncology reports Q2 EPS (90c), consensus (64c)
Reports Q2 revenue $1.16M, consensus $362,640. “This quarter we have made significant progress across our clinical, regulatory, manufacturing and commercial-readiness initiatives, positioning the Comp...
CG Oncology Earnings release: Q2 2026
CG Oncology released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
CG Oncology Quarterly report: Q2 2026
CG Oncology has published its Q2 2026 quarterly earnings report on August 6, 2026.
CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
DALLAS, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the second quarter ended June 30, 2026, and provided business updates.
CG Oncology announces publication of BOND-003 results in The Lancet Oncology
CG Oncology (CGON) announced the publication of results from the pivotal Phase 3 BOND-003 Cohort C trial evaluating cretostimogene grenadenorepvec monotherapy in patients with high-risk, Bacillus Calm...
CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorable safety and tolerability in patients with high-risk, BCG-unresponsive non-muscle invasive bladder ...
CG Oncology Slides: Investor presentation
CG Oncology has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
CG Oncology Slides: Conference presentation
CG Oncology has posted slides in relation to its latest quarterly earnings report, which was published on June 29, 2026.
CG Oncology 1.15M share Block Trade priced at $66.87
The deal range was $66.87-$67.87. Morgan Stanley acted as sole book running manager for the offering.
CG Oncology 1.15M share Block Trade; price range $66.87-$67.87
Morgan Stanley is acting as sole book running manager for the offering.